Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk | Zendy

Jeff S. Healey | Zendy; Robert G. Hart | Zendy; Janice Pogue | Zendy; Marc A. Pfeffer | Zendy; Stefan H. Hohnloser | Zendy; Raffaele De Caterina | Zendy; Greg Flaker | Zendy; Salim Yusuf | Zendy; Stuart J. Connolly | Zendy

Open Access

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk

Author(s) -

Jeff S. Healey,

Robert G. Hart,

Janice Pogue,

Marc A. Pfeffer,

Stefan H. Hohnloser,

Raffaele De Caterina,

Greg Flaker,

Salim Yusuf,

Stuart J. Connolly

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.500199

Subject(s) - medicine , clopidogrel , atrial fibrillation , aspirin , stroke (engine) , cardiology , stroke risk , warfarin , ischemic stroke , mechanical engineering , ischemia , engineering

In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research